An official website of the United States government
Audience
Attendees will include extramural academic researchers, geriatricians, NIH and NIA staff.
Dates
March 19, 2025 | 9:00 a.m. - 5:00 p.m. ET
Location
This meeting will be held virtually.
This virtual workshop is for NIH staff and select investigators.
Purpose and Background
There is convincing clinical evidence regarding the effects of incretin-mimetics on weight loss. It appears that the primary mechanism of action of single GLP-1RAs and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs is reduction in energy intake, while dual and triple combinations that include glucagon receptor agonists not only reduce energy intake but also increase energy expenditure. Findings from sufficiently powered clinical trials showed significant beneficial effects of incretin-mimetics on clinical aging-related outcomes, while data from earlier trials on the effects of these drugs on weight loss showed positive effects on the risk factors for diseases and conditions associated with aging. Several modern (GIP)/GLP-1RAs have been recently approved by the FDA for different indications and may become available to NIA-supported investigators in near future.
This workshop will discuss existing evidence in the topic area and ensuing discussions will inform NIA’s research directions on the effects of incretin-mimetics on aging-related mechanisms and disease and conditions associated with aging. Another important research topic is the potential differences in efficacy and safety of this class of drugs in older adults.
Agenda
All times are in Eastern Daylight Time. All talks are about 20 minutes plus 10 minutes for Q & As and discussions after each talk.
9:00 - 9:10 a.m. | Welcome and Introductions
9:10 - 9:20 a.m. | Charge to participants
9:20 - 9:50 a.m. | Incretin signaling pathway in health and disease, David A D'Alessio, M.D. , Duke University
9:50 - 10:20 a.m. | Incretins and circadian rhythm, diurnal variations in health and disease, Patricia L. Brubaker, Ph.D ., University of Toronto
The effects of incretin-mimetics on weight loss
10:20 - 10:50 a.m. | The effects of single incretin-mimetics on weight loss, John Wilding, D.M. FRCP , University of Liverpool
10:50 - 11:10 a.m. | Break
11:10 - 11:40 a.m. | The effects of dual and triple incretin-mimetics on weight loss, Robert Kushner, M.D. , Northwestern University
11:40 - 12:10 p.m. | Safety of incretin-mimetics, Jamy Ard, M.D. , Wake Forest University
The effects of incretin-mimetics on aging-related diseases and conditions
12:10 - 12:40 p.m. | The effects of incretin-mimetics on cardiovascular outcomes and their mechanism of action, Daniel J. Drucker, Ph.D. , Lunenfeld-Tanenbaum Research Institute, Toronto, CA
12:40 - 1:30 p.m. | Lunch
1:30 - 2:00 p.m. | Incretin-mimetics for the treatment of Heart Failure with Preserved Ejection Fraction, Dalane Kitzman, M.D. , Wake Forest University
2:00 - 2:30 p.m. | The effects of incretin-mimetics on brain and for treatment of dementias, Paul Edison, Ph.D. FRCPI , Imperial College of London
2:30 - 3:00 p.m. | Break
3:00 - 3:30 p.m. |The effects of incretin-mimetics on chronic kidney disease in patients with and without diabetes, T. Alp Ikizler, M.D. , Vanderbilt University
3:30 - 4:00 p.m. | The effects of incretin-mimetics on skeletal muscle, physical function, and QoL, Shalender Bhasin, M.D. , Brigham and Women’s Hospital
4:00 - 5:00 p.m. | Group discussion:
- Opportunities for trial on effects of incretin-mimetics on aging-related outcomes
- Conducting trials of caloric restriction and other nutritional interventions in the era of incretin-mimetics
5:00 p.m. | Adjourn
Contact Information
Please contact Irina Sazonova, PhD , for registration and other questions you may have about the workshop.
Reasonable Accommodations: If you need reasonable accommodation to participate in this event, please contact the meeting organizer listed under Contact information. Please make your request no later than 1 week before the event.